Analysis of cytokine-driven serum amyloid A expression based on the clinical results of IL-6 blocking therapy : a new cis-acting mechanism of STAT3

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Inflammation and Regeneration

• Publication date

  2006-09-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.2492/INFLAMMREGEN.26.453
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Essential role of STAT3 in cytokine‐driven NF‐κB‐mediated serum amyloid A gene expression

  2005cited by this paper
• Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

  2004cited by this paper
• IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system.

  2004cited by this paper
• NF-κB regulation in the immune system

  2002cited by this paper
• NF-?B regulation in the immune system

  2002cited by this paper
• Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.

  2001cited by this paper
• Interleukin 1β inhibits interleukin 6–mediated rat γ fibrinogen gene expression

  2000cited by this paper
• Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300.

  1999cited by this paper
• Serum amyloid A, the major vertebrate acute-phase reactant.

  1999cited by this paper
• IL-6-regulated transcription factors.

  1997cited by this paper
• STAT3 Participates in Transcriptional Activation of the C-reactive Protein Gene by Interleukin-6 (*)

  1996cited by this paper
• The Role of Cytokines in Rheumatoid Arthritis

  1996cited by this paper
• Anti-cytokine therapy in rheumatoid arthritis.

  1995cited by this paper
• The role of NF-kappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6.

  1993cited by this paper

• Refractory Sjögren's syndrome myelopathy successfully treated with subcutaneous tocilizumab

  2019cites this paper
• Serum Amyloid A Is a Marker for Pulmonary Involvement in Systemic Sclerosis

  2015cites this paper
• Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes

  2012cites this paper